- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.10. | Jazz and Roche's Zepzelca-Tecentriq wins FDA ES-SCLC approval | ||
| 06.10. | McMaster University and MIT discover new antibiotic for IBD | ||
| 03.10. | FDA approves mifepristone generic as political abortion war rages on | ||
| 03.10. | Takeda walks away from cell therapy in priority U-turn | ||
| 03.10. | Amgen's Phase III data supports FDA label expansion of Repatha | ||
| 02.10. | FDA winds down operations amid government shutdown | ||
| 02.10. | FDA leaders are "acting political", says ex-agency chief counsel | ||
| 02.10. | Halozyme eyes microparticles in $900m Elektrofi acquisition | ||
| 02.10. | AbbVie breaks ground on $70m US biologics site amid Trump pressure | ||
| 01.10. | US Government shuts down over funding impasse | ||
| 01.10. | Pfizer shakes hands with White House on drug discounts under MFN programme | ||
| 01.10. | Klotho to acquire Turn Biotechnologies' assets | ||
| 01.10. | Star Therapeutics gains $125m Series D funds to develop pipeline | ||
| 01.10. | Disruption due for long-held assumptions in biopharma, says BIA chair | ||
| 30.09. | Genmab to acquire Merus shares for $8bn | ||
| 30.09. | J&J gets FDA approval for Tremfya in paediatric psoriasis | ||
| 30.09. | NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing | ||
| 29.09. | Amgen to invest $650m in US manufacturing network expansion | ||
| 29.09. | Regeneron's Evkeeza gains FDA approval for young HoFH patients | ||
| 26.09. | AstraZeneca launches DTC platform amid US pricing pressures | ||
| 26.09. | Drugmakers point to US expansion plans amid Trump's 100% drug tariff | ||
| 26.09. | FDA approves Lilly's Inluriyo to treat advanced breast cancer | ||
| 26.09. | European PE company prioritising CGT and other novel modality investments | ||
| 26.09. | Harmony's cannabidiol drug flops in pivotal Fragile X Syndrome trial | ||
| 26.09. | Synaffix and Qurient enter licensing deal for dual-payload ADC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .